Compositions and methods for inhibiting the biological activity of soluble biomolecules
Inventors
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
NaNoticsNaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
NaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.
Publication Number
US-10420817-B2
Publication Date
2019-09-24
Expiration Date
Abstract
The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
Core Innovation
The invention relates to compositions of particles having at least one surface with an agent immobilized on the surface. The agent selectively binds to a target that is a first member of a specific binding pair, where the binding of the target to the particle inhibits the interaction of the target with a second member of the specific binding pair.
In the disclosed particles, the target is a soluble biomolecule in a form of a cell surface protein, such that the bound target is sequestered to render it inert and to inhibit downstream interactions with natural binding partners. The agent is disposed on the particle surface so that it is sterically inhibited from binding or activating the cell surface protein on the surface of a cell.
The disclosure further addresses particle configurations and surface shielding concepts, including steric inhibition via particle protrusions, ridges, and/or shielding features. It also provides additional strategies for in vivo clearance engineering, including reservoirs/coatings and coatings configured to increase clearance through renal clearance, hepatobiliary clearance, or phagocytosis pathways.
Claims Coverage
The independent claim is directed to a particle with an immobilized agent that selectively binds a soluble biomolecule that is a cell surface protein and thereby inhibits the target’s interaction with a second member of a specific binding pair, while the agent is sterically inhibited from binding or activating the cell surface protein on a surface of a cell. The dependent claims further refine the particle by specifying particular target classes, functional outcomes, particle sizing/dimensions constraints, and additional surface/coating and clearance-related limitations.
Immobilized selectively binding agent on a particle surface to inhibit binding-pair interaction
A particle having at least one surface and an agent immobilized on the surface, wherein the agent selectively binds to a target that is a first member of a specific binding pair and binding of the target to the particle inhibits the interaction of the target with a second member of the specific binding pair.
Soluble biomolecule cell-surface protein target and sterically inhibited agent disposition
The target is a soluble biomolecule, the soluble biomolecule is a form of a cell surface protein, and the agent is disposed on a surface of the particle such that it is sterically inhibited from binding or activating the cell surface protein on the surface of a cell.
Particle size constraint for nanoscale circulation
The particle has a diameter that is no greater than 300 nm, further specified as no greater than 250 nm.
Target soluble biomolecule as cytokine, chemokine, or enzyme
The soluble biomolecule is a cytokine, a chemokine, or an enzyme.
Coating configured to increase clearance via defined pathways
A coated particle has a coating that increases the particle’s clearance via phagocytosis, renal clearance, or hepatobiliary clearance.
No activation of a cell surface receptor protein
The agent does not activate a cell surface receptor protein.
Across the independent claim and dependents provided, the core coverage centers on a particle-immobilized agent that selectively binds a soluble cell-surface-protein biomolecule to inhibit the biomolecule’s interaction with a second binding-pair member, with additional steric inhibition to prevent binding/activation on cell surfaces, plus refinements including soluble biomolecule class, explicit particle diameter limits, coating-driven clearance pathways, and explicit prevention of receptor activation.
Stated Advantages
Inhibits interaction of the soluble biomolecule with natural binding partners by inhibiting interaction of the target with a second member of a specific binding pair.
Documented Applications
Cancer immune evasion / immune dis-inhibition contexts involving soluble shed receptor proteins such as soluble TNF receptors and soluble IL-2 receptors.
Detoxification uses and antiviral uses are described in the disclosure.
Interested in licensing this patent?